结直肠癌肝转移放射性栓塞的临床与影像预后因素:回顾性探索性分析
本研究回顾性分析22例结直肠癌肝转移患者共63个病灶,用FDG PET/CT评估经[90Y]树脂微球治疗后的病灶反应与吸收剂量关系,并探索临床与影像预后因素。结果显示平均剂量约50 Gy为显著反应临界阈值,剂量异质性为预后因素,TLG降低>65%与总生存改善独立相关。
要点
- 平均剂量>50 Gy的病灶可能获得显著反应,<20 Gy的病灶不太可能反应。
- 实测剂量异质性是显著预后因素,与平均剂量联合对反应的阳性预测值>80%。
- TLG降低>65%与总生存改善独立相关。
核心结论
- 接受平均剂量大于50 Gy的病灶可能获得显著反应,平均剂量小于20 Gy的病灶不太可能反应。
- 对于接受剂量小于50 Gy的病灶,剂量异质性是显著预后因素。
- TLG降低可能与总生存改善相关。
研究设计与样本
- 回顾性探索性分析,纳入22例结直肠癌肝转移患者共63个病灶。
- 采用FDG PET/CT测量单个病灶对实测吸收剂量的反应,实测剂量来自治疗后90Y PET显像。
- 预测剂量来自规划[99mTc]-MAA SPECT数据。
主要发现
- 预测剂量与实测剂量之间一致性差。
- TLG是更优的反应指标,所有剂量指标均为显著预后因素,平均剂量约50 Gy为显著反应(TLG降低>50%)的临界阈值。
- 基线TLG或RAS突变状态与反应无显著相关性。
- 实测剂量异质性是显著预后因素,与平均剂量联合对反应的阳性预测值>80%。
- 在生存预后探索性分析中,低肝脏肿瘤负荷和TLG平均降低>65%与总生存改善独立相关。
关键数值与推荐
- 平均剂量约50 Gy为显著反应(TLG降低>50%)的临界阈值。
- 平均剂量小于20 Gy的病灶不太可能反应。
- 实测剂量异质性与平均剂量联合对反应的阳性预测值>80%。
- TLG平均降低>65%与总生存改善独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to investigate the relationship between absorbed dose and response of colorectal cancer liver metastases treated with [90Y]-resin microspheres and to explore possible clinical and imaging derived prognostic factors. METHODS: FDG PET/CT was used to measure response of individual lesions to a measured absorbed dose, derived from post-treatment 90Y PET imaging. Predicted dose was also derived from planning [99mTc]-MAA SPECT data. Peak standardised uptake value and total lesion glycolysis (TLG) were explored as response measures, and compared to dose metrics including average dose (D avg), biologically effective dose, minimum dose to 70% of lesion volume and volume receiving at least 50 Gy. Prognostic factors examined included baseline TLG, RAS mutation status, FDG heterogeneity and dose heterogeneity. In an exploratory analysis, response and clinico-pathological variables were evaluated and compared to overall survival. RESULTS: Sixty-three lesions were analysed from 22 patients. Poor agreement was seen between predicted and measured dose values. TLG was a superior measure of response, and all dose metrics were significant prognostic factors, with a D avg of ~50 Gy derived as the critical threshold for a significant response (>50% reduction in TLG). No significant correlation was found between baseline TLG or RAS mutation status and response. Measured dose heterogeneity was a significant prognostic factor and when combined with D avg had a positive predictive value for response >80%. In the exploratory analysis for prognostic factors of survival, low hepatic tumour burden and mean reduction in TLG >65% were independently associated with improved overall survival. CONCLUSIONS: Lesions receiving an average dose greater than 50 Gy are likely to have a significant response. For lesions receiving less than 50 Gy, dose heterogeneity is a significant prognostic factor. Lesions receiving an average dose less than 20 Gy are unlikely to respond. A reduction in TLG may be associated with improved overall survival.
引用
- Willowson KP, Hayes AR, Chan DLH, et al. Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. EJNMMI Res. 2017. PMID: 28536968. doi:10.1186/s13550-017-0292-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。